India, Dec. 22 -- image credit- freepik

PlasmaGen Biosciences, a leading biopharmaceutical company focused on blood plasma-derived therapeutics, has raised Rs 150 crore in a minority equity financing round at an Rs 1500+ crore valuation. The round was led by ViNS Bioproducts, a specialty biopharma company, with participation from prominent HNI family offices, pharmaceutical entrepreneurs and existing investors.

The financing reflects strong investor conviction in PlasmaGen's operating model, manufacturing infrastructure, and long-term potential as a differentiated plasma biopharmaceutical platform. Since commencing commercial operations at its state-of-the-art manufacturing facility in 2024 - India's first such facility by a pure-play c...